Comments on: Minimising risks: drug discovery practices for Chief Scientific Officers

By: teixeiracs

teixeiracs — Sat, 27 Feb 2010 20:01:47 +0000

The ideas discussed by you, Marcus Evans, are too relevant. People ever go toward drugstores or hospitals prioritizing their health, but the recent financial availability may inibe the buying consumer disposition, thus the economic turbulence demands smarter actions from pharmaceutical corporations which includes the expensive drug discovery universe, also. All hope that pharma decision makers will administrate their budgets respecting company financial performances, the investor satisfaction, regulatory and sanitary requirements and the consumer necessities. We, professionals, health authorities, universities and companies must be ready for this opportunity.

By: amino

amino — Wed, 10 Feb 2010 18:19:58 +0000

Too many to cover in one article – there’s so much coming through. Just look at the money being poured into drug development diagnostics at the moment. It’s the future.

By: tut

tut — Tue, 09 Feb 2010 20:24:14 +0000

Interesting piece. I suspect there will be an abundance of new technologies come through in the next few years which we are just starting to see emerge that are focussed on predicting in vivo efficacy more accurately and improving success rates in discovery. It would be great to see an article summarising some of these technologies.